Singular Genomics Systems, Inc. Announces Board and Committee Appointments
January 07, 2022 at 02:35 am IST
Share
Singular Genomics Systems, Inc. announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Since 2016, Dr. Mardis has served as Co-Executive Director of the Institute of Genomic Medicine at Nationwide Children's Hospital and holds the Steve and Cindy Rasmussen Endowed Chair in Genomic Medicine. She is also Professor of Pediatrics at The Ohio State University College of Medicine. Also, on January 5, 2022, the Board authorized and established the Science and Technology Committee to oversee
science and technology matters of the Company. The Board appointed Eli Glezer, Ph.D. to serve as Chair of the Science and Technology Committee, and appointed Dr. Mardis and David Barker to serve as committee members.
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.
SINGULAR GENOMICS SYSTEMS, INC. 
